ArticleHuman vaccines & immunotherapeutics2025
A One Health approach to bovine coronavirus vaccine development, using LSDV as a live virus vector.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Farm animal coronaviruses: the solution is in vaccines.The veterinary quarterly · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine coronavirus (BCoV) causes significant pneumo-enteric infections in cattle and other ruminants. A BCoV-like coronavirus was previously found in a symptomatic human child and shares 97.1% sequence identity with one of the more prevalent human coronaviruses, HCoV-OC43. Zoonosis of a virulent BCoV from livestock is a feasible threat. Lumpy skin disease virus (LSDV) is a poxvirus that can be used as a live attenuated dual vaccine vector in cattle and potentially as a replication-deficient vaccine vector, in humans. This paper explores the development of a vaccine, considering the increasingly significant One Health approach, which recognizes the importance of curbing disease at the animal-human interface to prevent future epizootics and pandemics. A recombinant LSDV (LSDV-BCoV-K1L) was developed to express the spike and nucleocapsid proteins of BCoV. The spike and nucleocapsid antigens used in this vaccine were derived from consensus sequences of 38 spike and 24 nucleocapsid amino acid sequences, encompassing multiple BCoV genotypes. The insertion of the foreign gene cassette between LSDV open reading frames 49 and 50 was verified using polymerase chain reaction and DNA sequencing. Furthermore, western blot analysis confirmed the expression of BCoV spike and nucleocapsid proteins in cells infected with LSDV-BCoV-K1L. The immunogenicity of LSDV-BCoV-K1L was evaluated in mice and compared to the parent virus, nLSDVSODis-UCT. Mice immunized with LSDV-BCoV-K1L produced nucleocapsid-specific T-cells and high levels of spike-specific antibodies. This combined vaccine targeting both lumpy skin disease virus and BCoV requires further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.